Setanaxib is a novel pyrazolopyridine derivative categorized as an NADPH oxidase inhibitor, currently under investigation for its potential in treating inflammatory conditions such as rheumatoid arthritis… Read more
Setanaxib is a novel pyrazolopyridine derivative categorized as an NADPH oxidase inhibitor, currently under investigation for its potential in treating inflammatory conditions such as rheumatoid arthritis and psoriasis. This category contains high-quality reference standards for Setanaxib, alongside a range of its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories rely on these specialized materials to perform rigorous impurity profiling and ensure accurate quantification during analytical testing. By utilizing these precise standards, researchers and quality control analysts can effectively develop and validate robust analytical methods, ensuring the characterization of both the active pharmaceutical ingredient and its related degradation products throughout the drug development lifecycle.